Veerman G - Search Results

1

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Cancer Res. 1994 Aug 1;54(15):4138-43. Cancer Res. 1994. PMID: 8033147

2

Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).

Ruiz van Haperen VW, Veerman G, Noordhuis P, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Adv Exp Med Biol. 1991;309A:57-60. doi: 10.1007/978-1-4899-2638-8_12. Adv Exp Med Biol. 1991. PMID: 1789270 No abstract available.

3

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Semin Oncol. 1995 Aug;22(4 Suppl 11):35-41. Semin Oncol. 1995. PMID: 7481843

4

Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Braakhuis BJ, et al. Among authors: veerman g. Semin Oncol. 1995 Aug;22(4 Suppl 11):42-6. Semin Oncol. 1995. PMID: 7481844

5

Interaction between cisplatin and gemcitabine in vitro and in vivo.

Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Peters GJ, et al. Among authors: veerman g. Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9. Semin Oncol. 1995. PMID: 7481849

6

Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.

Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Bergman AM, et al. Among authors: veerman g. Adv Exp Med Biol. 1994;370:139-43. doi: 10.1007/978-1-4615-2584-4_32. Adv Exp Med Biol. 1994. PMID: 7660877 No abstract available.

7

In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of five organotin compounds.

Gielen M, Willem R, Bouhdid A, De Vos D, Kuiper CM, Veerman G, Peters GJ. Gielen M, et al. Among authors: veerman g. In Vivo. 1995 Jan-Feb;9(1):59-63. In Vivo. 1995. PMID: 7669950

8

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.

Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Biochem Pharmacol. 1994 Oct 7;48(7):1327-39. doi: 10.1016/0006-2952(94)90554-1. Biochem Pharmacol. 1994. PMID: 7945430

9

Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.

Ruiz van Haperen VW, Veerman G, Braakhuis BJ, Vermorken JB, Boven E, Leyva A, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Eur J Cancer. 1993;29A(15):2132-7. doi: 10.1016/0959-8049(93)90048-k. Eur J Cancer. 1993. PMID: 8297652

10

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.

Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Among authors: veerman g. Biochem Pharmacol. 1993 Aug 17;46(4):762-6. doi: 10.1016/0006-2952(93)90566-f. Biochem Pharmacol. 1993. PMID: 8363650

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters